The introduction of the GLP-1 class of medications for weight loss has, to date, been one of the rockiest rollouts of a major medical advance in the United States
This makes it a subject of significant interest in wound healing and chronic inflammation research
compiled from community dosing logs and reconstitution guides documentation of what sources describe, not a recommendation): Self-reported starting doses begin around 125 mcg weekly for 2-4 weeks to assess tolerance, before increasing to 250 mcg
Whether you are starting your first tirzepatide protocol or switching from a different vial size, the charts below will eliminate the guesswork
others provide what appear to be COAs but are templated documents without batch-specific data, or COAs that list only a purity figure without the underlying chromatogram
doi: 10.1002/jmv.24692 18